Nrg-Gu006- A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial Of Salvage Radiotherapy With Or Without Enhanced Anti-Androgen Therapy With Apalutamide In Recurrent Prostate Cancer.
Posted Date: May 15, 2019
- Investigator: Timothy Struve
- Specialties: Cancer, Oncology, Prostate Cancer
- Type of Study: Drug
To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone
Criteria:
To Be Eligible: Age 18 Or Older, Must Have Prostate Cancer And Have Had A Prostatectomy,No Current Metastatic Disease,
Keywords:
Prostate Cancer, Phase Ii, Oncology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com